277 related articles for article (PubMed ID: 21865319)
1. Differences in the disposition of silymarin between patients with nonalcoholic fatty liver disease and chronic hepatitis C.
Schrieber SJ; Hawke RL; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Meyers CM; Doo E; Fried MW
Drug Metab Dispos; 2011 Dec; 39(12):2182-90. PubMed ID: 21865319
[TBL] [Abstract][Full Text] [Related]
2. The pharmacokinetics of silymarin is altered in patients with hepatitis C virus and nonalcoholic Fatty liver disease and correlates with plasma caspase-3/7 activity.
Schrieber SJ; Wen Z; Vourvahis M; Smith PC; Fried MW; Kashuba AD; Hawke RL
Drug Metab Dispos; 2008 Sep; 36(9):1909-16. PubMed ID: 18566043
[TBL] [Abstract][Full Text] [Related]
3. Role of UDP-Glucuronosyltransferase 1A1 in the Metabolism and Pharmacokinetics of Silymarin Flavonolignans in Patients with HCV and NAFLD.
Xie Y; Miranda SR; Hoskins JM; Hawke RL
Molecules; 2017 Jan; 22(1):. PubMed ID: 28098838
[TBL] [Abstract][Full Text] [Related]
4. Silymarin ascending multiple oral dosing phase I study in noncirrhotic patients with chronic hepatitis C.
Hawke RL; Schrieber SJ; Soule TA; Wen Z; Smith PC; Reddy KR; Wahed AS; Belle SH; Afdhal NH; Navarro VJ; Berman J; Liu QY; Doo E; Fried MW;
J Clin Pharmacol; 2010 Apr; 50(4):434-49. PubMed ID: 19841158
[TBL] [Abstract][Full Text] [Related]
5. Pharmacokinetics and metabolic profile of free, conjugated, and total silymarin flavonolignans in human plasma after oral administration of milk thistle extract.
Wen Z; Dumas TE; Schrieber SJ; Hawke RL; Fried MW; Smith PC
Drug Metab Dispos; 2008 Jan; 36(1):65-72. PubMed ID: 17913795
[TBL] [Abstract][Full Text] [Related]
6. An assessment of pharmacokinetics and antioxidant activity of free silymarin flavonolignans in healthy volunteers: a dose escalation study.
Zhu HJ; Brinda BJ; Chavin KD; Bernstein HJ; Patrick KS; Markowitz JS
Drug Metab Dispos; 2013 Sep; 41(9):1679-85. PubMed ID: 23835761
[TBL] [Abstract][Full Text] [Related]
7. Hepatic metabolism and biliary excretion of silymarin flavonolignans in isolated perfused rat livers: role of multidrug resistance-associated protein 2 (Abcc2).
Miranda SR; Lee JK; Brouwer KL; Wen Z; Smith PC; Hawke RL
Drug Metab Dispos; 2008 Nov; 36(11):2219-26. PubMed ID: 18687803
[TBL] [Abstract][Full Text] [Related]
8. Hepatic organic anion transporting polypeptides mediate disposition of milk thistle flavonolignans and pharmacokinetic silymarin-drug interactions.
Lynch KD; Montonye ML; Tian DD; Arman T; Oyanna VO; Bechtold BJ; Graf TN; Oberlies NH; Paine MF; Clarke JD
Phytother Res; 2021 Jun; 35(6):3286-3297. PubMed ID: 33587330
[TBL] [Abstract][Full Text] [Related]
9. The effect of milk thistle (Silybum marianum) and its main flavonolignans on CYP2C8 enzyme activity in human liver microsomes.
Albassam AA; Frye RF; Markowitz JS
Chem Biol Interact; 2017 Jun; 271():24-29. PubMed ID: 28457856
[TBL] [Abstract][Full Text] [Related]
10. The study of flavonolignan association patterns in fruits of diverging Silybum marianum (L.) Gaertn. chemotypes provides new insights into the silymarin biosynthetic pathway.
Martinelli T; Whittaker A; Benedettelli S; Carboni A; Andrzejewska J
Phytochemistry; 2017 Dec; 144():9-18. PubMed ID: 28863306
[TBL] [Abstract][Full Text] [Related]
11. Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.
Brantley SJ; Oberlies NH; Kroll DJ; Paine MF
J Pharmacol Exp Ther; 2010 Mar; 332(3):1081-7. PubMed ID: 19934397
[TBL] [Abstract][Full Text] [Related]
12. A Randomized Trial of Silymarin for the Treatment of Nonalcoholic Steatohepatitis.
Wah Kheong C; Nik Mustapha NR; Mahadeva S
Clin Gastroenterol Hepatol; 2017 Dec; 15(12):1940-1949.e8. PubMed ID: 28419855
[TBL] [Abstract][Full Text] [Related]
13. Silybin, a Major Bioactive Component of Milk Thistle (Silybum marianum L. Gaernt.)-Chemistry, Bioavailability, and Metabolism.
Bijak M
Molecules; 2017 Nov; 22(11):. PubMed ID: 29125572
[TBL] [Abstract][Full Text] [Related]
14. Relative Bioavailability of Silybin A and Silybin B From 2 Multiconstituent Dietary Supplement Formulations Containing Milk Thistle Extract: A Single-dose Study.
Li WY; Yu G; Hogan RM; Mohandas R; Frye RF; Gumpricht E; Markowitz JS
Clin Ther; 2018 Jan; 40(1):103-113.e1. PubMed ID: 29273470
[TBL] [Abstract][Full Text] [Related]
15. Bioavailability of a silybin-phosphatidylcholine complex in dogs.
Filburn CR; Kettenacker R; Griffin DW
J Vet Pharmacol Ther; 2007 Apr; 30(2):132-8. PubMed ID: 17348898
[TBL] [Abstract][Full Text] [Related]
16. Systematic review of pharmacokinetics and potential pharmacokinetic interactions of flavonolignans from silymarin.
Tvrdý V; Pourová J; Jirkovský E; Křen V; Valentová K; Mladěnka P
Med Res Rev; 2021 Jul; 41(4):2195-2246. PubMed ID: 33587317
[TBL] [Abstract][Full Text] [Related]
17. Milk thistle (Silybum marianum): A concise overview on its chemistry, pharmacological, and nutraceutical uses in liver diseases.
Abenavoli L; Izzo AA; Milić N; Cicala C; Santini A; Capasso R
Phytother Res; 2018 Nov; 32(11):2202-2213. PubMed ID: 30080294
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetic studies on IdB 1016, a silybin- phosphatidylcholine complex, in healthy human subjects.
Barzaghi N; Crema F; Gatti G; Pifferi G; Perucca E
Eur J Drug Metab Pharmacokinet; 1990; 15(4):333-8. PubMed ID: 2088770
[TBL] [Abstract][Full Text] [Related]
19. Identification of hepatoprotective flavonolignans from silymarin.
Polyak SJ; Morishima C; Lohmann V; Pal S; Lee DY; Liu Y; Graf TN; Oberlies NH
Proc Natl Acad Sci U S A; 2010 Mar; 107(13):5995-9. PubMed ID: 20231449
[TBL] [Abstract][Full Text] [Related]
20. Milk thistle and prostate cancer: differential effects of pure flavonolignans from Silybum marianum on antiproliferative end points in human prostate carcinoma cells.
Davis-Searles PR; Nakanishi Y; Kim NC; Graf TN; Oberlies NH; Wani MC; Wall ME; Agarwal R; Kroll DJ
Cancer Res; 2005 May; 65(10):4448-57. PubMed ID: 15899838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
